Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2007-08-02
2008-11-25
Navarro, Mark (Department: 1645)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S069100, C435S069700, C435S071100, C435S071200, C435S252300, C435S252330, C435S320100, C536S023400
Reexamination Certificate
active
07456272
ABSTRACT:
Modified neurotoxins that contain protease cleavage sites susceptible uniquely to proteases present in certain tissues are described. The toxins can be selectively activated by proteases in muscle or selectively inactivated by proteases in blood.
REFERENCES:
patent: 5562907 (1996-10-01), Arnon
patent: 5728399 (1998-03-01), Wu et al.
patent: 5763250 (1998-06-01), Williams et al.
patent: 5837265 (1998-11-01), Montel et al.
patent: 5939070 (1999-08-01), Goodnough et al.
patent: 5989545 (1999-11-01), Foster et al.
patent: 6022950 (2000-02-01), Murphy
patent: 6066621 (2000-05-01), Sela et al.
patent: 6087327 (2000-07-01), Pearce et al.
patent: 6113946 (2000-09-01), Szoka et al.
patent: 6203794 (2001-03-01), Dolly et al.
patent: 6221355 (2001-04-01), Dowdy
patent: 6312708 (2001-11-01), Donovan
patent: 6333303 (2001-12-01), Borgford
patent: 6342221 (2002-01-01), Thorpe et al.
patent: 6361938 (2002-03-01), O'Mahony et al.
patent: 6383775 (2002-05-01), Duff et al.
patent: 6395513 (2002-05-01), Foster et al.
patent: 6416959 (2002-07-01), Giuliano
patent: 6426075 (2002-07-01), Fitzgerald et al.
patent: 6444209 (2002-09-01), Johnson et al.
patent: 6461617 (2002-10-01), Shone et al.
patent: 6670147 (2003-12-01), Heidtmann et al.
patent: 7056729 (2006-06-01), Donovan
patent: 7132259 (2006-11-01), Dolly et al.
patent: 7262291 (2007-08-01), Donovan
patent: 7273722 (2007-09-01), Lin et al.
patent: 2002/0045208 (2002-04-01), Eck et al.
patent: 2002/0177545 (2002-11-01), Donvan
patent: 2006/0099672 (2006-05-01), Dolly et al.
patent: 2007/0259003 (2007-11-01), Donovan
patent: 2007/0259401 (2007-11-01), Dolly et al.
patent: 2008/0032930 (2008-02-01), Steward et al.
patent: 2008/0096248 (2008-04-01), Steward et al.
patent: 95/32738 (1995-12-01), None
patent: 98/07864 (1998-02-01), None
patent: 98/20135 (1998-05-01), None
patent: 00/61768 (2000-10-01), None
patent: 01/14570 (2001-03-01), None
Li Yan et al, “Expression and characterization of the heavy chain of tetanus toxin: Reconstitution of the fully-recombinant dichain protein in the active form”, Journal of Biochemistry, vol. 125, No. 6, Jun. 1999, pp. 1200-1208.
Ashton Anthony et al, “Tetanus toxin inhibits neuroexocytosis even when its Zn-2+-dependent protease activity is removed”, Journal of Biological Chemistry, vol. 270, No. 52, 1995, pp. 31386-31390.
Aravamudan et al, Journal of Neurobiology, vol. 54, pp. 417-438, 2003.
Bryant et al, The EMBO Journal, vol. 20, pp. 3380-3388, 2001.
Hayashi et al, Plant and Cell physiology (Japan), Sep. 2001, vol. 42-9, pp. 894-899.
Flaumenhaft, Arteriosclerosis, thrombosis and vascular biology, Jul. 1, 2003, vol. 23(7), pp. 1152-1160.
Ernst, Cellular Microbiology, vol. 2(5) pp. 379-386, 2000.
Borodic et al, “Pharmacology and Histology of the Therapeutic Application of Botulinum Toxin”, In Therapy with Botulinum Toxin, pp. 119-157, 1994.
Chaddock et al, Infection and Immunity, vol. 68(5), pp. 2587-2593, May 2000.
Zhou et al, Biochemistry, vol. 34(46), pp. 15175-15181, 1995.
Aoki et al, Eur. J. Neurol., vol. 6 (suppl 4), pp. S3-S10, 1999.
Carter, Chapter 13, Site specific proteolysis of Fusion proteins, pp. 181-193, American Chemistry Society, In Protein Purification: From Molecular Mechanisms to Large Scale Processes.
Niemann et al, Trends in Cell Biology, vol. 4, pp. 179-185, 1994.
O'hara et al, FEBS, vol. 273(1-2), pp. 200-204, Oct. 1990.
Robinson et al, Journal of Biological Chemistry, vol. 250(18), pp. 7435-7442, Sep. 25, 1975.
Woody et al, Toxicon, vol. 27(10), pp. 1143-1150, 1989.
Yan et al, Biochemistry, Vo. 33(22), pp. 7014-7020, 1994.
Montecucco et al, Trends in biochemistry, vol. 18,, pp. 324-327, 1993.
Walker et al, Bio/Technology, vol. 12, pp. 601-605, Jun. 1994.
Aoki Kei Roger
Lin Wei-Jen
Steward Lance E.
Allergan Inc.
German Joel B.
Navarro Mark
Portner Ginny
Stathakis Dean G.
LandOfFree
Neurotoxins with enhanced target specificity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Neurotoxins with enhanced target specificity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neurotoxins with enhanced target specificity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4043148